AKT1 and neoplasm: GSK3 appeared highly expressed in osteosarcoma and targeting Akt/GSK3/β-catenin or Akt/GSK3-/Notch-1, respectively, with dioscein or tideglusib repressed CSC and tumor growth[107,108].